Startseite
QUALITYISO9001:2015
H(

Halolife (Xiamen) Technology Co., Ltd.

425
19
9
4.4(79)

Über das Unternehmen

  • Firmenname (rechtlich): Halolife (Xiamen) Technology Co., Ltd.
  • Internationaler Name: 厦门海乐景科技有限公司 (Halolife (Xiamen) Technology Co., Ltd.), Xiamen, Fujian, China
  • Marke / Handelsname: Halolife
  • Registrierungsland: China
  • Adresse: Fujian
Beschreibung:

Established in 2012, Halolife (Xiamen) Technology Co., Ltd. supplies specialized reagents and chiral intermediates, offering contract manufacturing (CMO) to customers across the Americas, Europe, Asia, the Middle East, Africa, and Australasia. Payment is accepted via T/T or L/C, and the company is noted for its experienced R&D staff, reliable delivery, and quality service.

Geschäftsaktivitäten

Pharmazeutische Chemikalien

HerstellerAnbieter für AuftragssyntheseAPI-Hersteller

Pharmazeutische Wirkstoffe (API)

API-Hersteller

Laborchemikalien, Lösungsmittel & Referenzstandards

API-Hersteller

Unsere Produkte & Dienstleistungen

Sell · Laboratory Chemicals, Solvents & Reference Standards
Sofosbuvir
Sell · Laboratory Chemicals, Solvents & Reference Standards
Sofosbuvir Intermediate 4
Sell · Laboratory Chemicals, Solvents & Reference Standards
Obeticholic Acid Intermediate 1
Sell · Laboratory Chemicals, Solvents & Reference Standards
Entecavir
Sell · Laboratory Chemicals, Solvents & Reference Standards
Entecavir intermediate...
Sell · Laboratory Chemicals, Solvents & Reference Standards
Obeticholic Acid
Sell · Laboratory Chemicals, Solvents & Reference Standards
Obeticholic Acid Intermediate B
Sell · Laboratory Chemicals, Solvents & Reference Standards
Obeticholic Acid Intermediate E1
Sell · Laboratory Chemicals, Solvents & Reference Standards
Sofosbuvir Intermediate 1
Sell · Laboratory Chemicals, Solvents & Reference Standards
Sofosbuvir Intermediate 2
Sell · Laboratory Chemicals, Solvents & Reference Standards
Sofosbuvir Intermediate 3
Sell · Laboratory Chemicals, Solvents & Reference Standards
Sofosbuvir Intermediate 5
Filter:
Sortieren nach:

    Keine Kommentare verfügbar.